Umbrella Organization of European Waldenström patient supportgroups and patients


Revised IWMF Ibrutinib Fact Sheet

Go back to newsInserted on Thursday 2 August 2018
Ibrutinib was the first drug that was approved by the US Food and Drug Administration (FDA) specifically for Waldenstrom’s macroglobulinemia (WM). In the past couple of years there has been an explosion of research on ibrutinib of special interest to patients with WM and their caregivers. This newly revised IWMF Ibrutinib Fact Sheet introduces the interested reader to updates on the targeted therapy. New information is provided on dosing, side effects, and useful self-care tips. The updated fact sheet is available in English, Chinese (both Simplified and Traditional), French, German, Italian, Spanish, and Norwegian. They all can be downloaded at

Recent articles

News archive

This is a website under permanent construction made by WM patients for WM patients.We will add new information in due time.
Disclaimer : By your use of the EWMnetwork for information and communication you relieve EWMnetwork of any responsibility
for the content of this website. Links to third-party sites appearing on this website are supplied for information only and EWMnetwork
cannot be held liable for the content or management of any such sites.